PMID- 18481381
OWN - NLM
STAT- MEDLINE
DCOM- 20080612
LR  - 20181201
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 31
IP  - 2
DP  - 2008 Feb-Mar
TI  - Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor 
      antibody and targeted to activating FcgammaRs on human dendritic cells.
PG  - 113-20
LID - 10.1097/CJI.0b013e31815a5892 [doi]
AB  - The induction of effective immune responses to tumor vaccines requires the 
      preferential activation of effector T cells relative to regulatory or suppressive 
      T cells. Glial tumors commonly overexpress the epidermal growth factor receptor 
      (EGFR), which can be targeted by monoclonal antibodies. Here we show that the 
      coating of glial tumor cells with a clinical grade anti-EGFR antibody, cetuximab, 
      leads to enhanced tumor-specific, interferon-gamma producing CD8+ T cells by 
      dendritic cells (DCs). The selective targeting of monoclonal antibody coated 
      glioma cells to activating Fcgamma receptors (FcgammaRs) on DCs, which is 
      achieved with a blocking antibody to the inhibitory form of FcgammaR, leads to 
      the induction of antitumor immunity without the need for an exogenous maturation 
      stimulus. Importantly, this approach reduces the concurrent induction of 
      regulatory T cells, which can also be depleted to further enhance immunity. These 
      data suggest that immunity to EGFR expressing tumors, including glioma, can be 
      enhanced through the concerted function of antitumor monoclonal antibodies, 
      activating FcgammaR, and DCs.
FAU - Banerjee, Devi
AU  - Banerjee D
AD  - Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New 
      York, NY 10021, USA.
FAU - Matthews, Phillip
AU  - Matthews P
FAU - Matayeva, Elyana
AU  - Matayeva E
FAU - Kaufman, Jacob L
AU  - Kaufman JL
FAU - Steinman, Ralph M
AU  - Steinman RM
FAU - Dhodapkar, Kavita M
AU  - Dhodapkar KM
LA  - eng
GR  - AI054375/AI/NIAID NIH HHS/United States
GR  - M01-RR00102/RR/NCRR NIH HHS/United States
GR  - P01-AI51573/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (FCGR2B protein, human)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Interleukin-2 Receptor alpha Subunit)
RN  - 0 (Receptors, IgG)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antibodies, Monoclonal/immunology/*pharmacology
MH  - Antibodies, Monoclonal, Humanized
MH  - Antigen Presentation/drug effects/immunology
MH  - Antineoplastic Agents/immunology/pharmacology
MH  - CD8-Positive T-Lymphocytes/*immunology/metabolism
MH  - Cell Differentiation/immunology
MH  - Cell Line, Tumor
MH  - Cetuximab
MH  - Chemokines/metabolism/pharmacology
MH  - Coculture Techniques
MH  - Cytokines/metabolism
MH  - Dendritic Cells/*drug effects/immunology
MH  - ErbB Receptors/*immunology/metabolism
MH  - Forkhead Transcription Factors/analysis
MH  - Glioma/immunology/metabolism/pathology
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Interleukin-2 Receptor alpha Subunit/analysis
MH  - Lymphocyte Activation/drug effects/immunology
MH  - Receptors, IgG/*immunology/metabolism
MH  - T-Lymphocytes, Regulatory/drug effects/immunology/metabolism
EDAT- 2008/05/16 09:00
MHDA- 2008/06/13 09:00
CRDT- 2008/05/16 09:00
PHST- 2008/05/16 09:00 [pubmed]
PHST- 2008/06/13 09:00 [medline]
PHST- 2008/05/16 09:00 [entrez]
AID - 00002371-200802000-00001 [pii]
AID - 10.1097/CJI.0b013e31815a5892 [doi]
PST - ppublish
SO  - J Immunother. 2008 Feb-Mar;31(2):113-20. doi: 10.1097/CJI.0b013e31815a5892.